AR044495A1 - Amidas sustituidas de acido carboxilico, su preparacion y su uso como medicamentos - Google Patents

Amidas sustituidas de acido carboxilico, su preparacion y su uso como medicamentos

Info

Publication number
AR044495A1
AR044495A1 ARP030104741A ARP030104741A AR044495A1 AR 044495 A1 AR044495 A1 AR 044495A1 AR P030104741 A ARP030104741 A AR P030104741A AR P030104741 A ARP030104741 A AR P030104741A AR 044495 A1 AR044495 A1 AR 044495A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
substituted
amino
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Suspension/Interruption
Application number
ARP030104741A
Other languages
English (en)
Inventor
Bauer Eckhart Dr
James Gillard
Dahmann Georg Dr
Gerlach Kai Dr
Handschuh Sandra Ruth Dr
Nar Herbert Dr
Pfau Roland Dr
Priepke Henning Dr
Wienen Wolfgang Dr
Schuler-Metz Annette Mario Dr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2002159407 external-priority patent/DE10259407A1/de
Priority claimed from DE10335545A external-priority patent/DE10335545A1/de
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR044495A1 publication Critical patent/AR044495A1/es
Suspension/Interruption legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

Amidas substituidas de ácido carboxílico de fórmula general (1) en la que R1 representa un grupo amino, alquilamino C1-5, cicloalquilamino C3-7 o un grupo (fenilalquilo C1-3)-amino que en su caso pueden estar substituidos en el átomo de nitrógeno amínico adicionalmente con un grupo fenilcarbonilo o fenilsulfonilo o con un grupo en su caso substituido en la parte alquilo con un grupo hidroxi, un grupo alquiloxi C1-3 o un grupo carboxi un grupo que puede transformarse in vivo en un grupo carboxi un grupo alquilo C1-5 o alquilcarbonilo C1-5 substituido con amino, alquilamino C1-3, di-(alquil C1-3)-amino o un grupo cicloalquilenimino de 4 a 7 miembros, en donde en el grupo alquilo C1-5 substituido indicado precedentemente, dos heteroátomos están separados entre sí por al menos dos átomos de carbono, un grupo cicloalquileniminocarbonilo o cicloalquileniminosulfonilo de 4 a 7 miembros, en donde la parte cicloalquilenimino de la estructura carbonada puede estar substituida con un átomo de flúor, cloro o bromo, uno o dos grupos alquilo C1-3, alquenilo C2-3, alquinilo C2-3, hidroxi-alquilo C1-3, alquiloxi C1-3-alquilo, fenilalquilo C1-3, difenilalquilo C1-3, heteroarilalquilo C1-3, aminoalquilo C1-3, cicloalquilamino C3- 6-alquilo C1-3, fenilamino-alquilo C1-3, alquilamino C1-5-alquilo C1-3, di-(alquil C1-5)-amino-alquilo C1-3, N-(cicloalquil C3-6)-alquilamino C1-3-alquilo C1-3, un grupo cicloalquileniminoalquilo C1-3 de 4 a 7 miembros, N-(alquilcarbonil C1- 3)alquilamino C1-3-alquilo C1-3, un grupo carboxi-alquilo C1-3, alquiloxicarbonil C1-3alquilo C1-3, aminocarbonilalquilo C1-3, alquilaminocarbonil C1-3alquilo C1-3, di-(alquil C1-3)-aminocarbonilalquilo C1-3, un grupo cicloalquileniminocarbonilalquilo C1-3 de 4 a 7 miembros, un grupo alquiloxicarbonilamino C1-5-alquilo C1-3, alquilcarbonilamino C1-3-alquilo C1-3, alquilsulfonilamino C1-3-alquilo C1-3, aminocarbonilamino-alquilo C1-3, alquilaminocarbonilamino C1-3- alquilo C1-3, di-(alquil C1-3)-aminocarbonilamino-alquilo C1-3, carboxi, alquiloxicarbonilo C1-3, benciloxicarbonilo, alquilcarbonilo C1-3, aminocarbonilo, alquilamino C1-3-carbonilo, di-(alquil C1-3)-aminocarbonilo, N-(cicloalquil C3-7)- alquilaminocarbonilo C1-5, N-(fenilalquil C1-3)-alquilaminocarbonilo C1-5, un grupo cicloalquileniminocarbonilo de 4 a 7 miembros, un grupo aminocarbonil C1-3-alquilaminocarbonilo C1-3, hidroxi, alquiloxi C1-3, aliloxi, propargiloxi, benciloxi, amino, alquilamino C1-3, di-(alquil C1-3)-amino, un grupo cicloalquilenimino C1-3, trifluormetilcarbonilamino, un grupo mono, di o trifluormetilamino, un grupo fenilo o un grupo heteroarilo de 5 a 6 miembros con la condición de que en la substitución de un grupo metileno adyacente al grupo imino, dos heteroátomos estén separados entre sí por al menos dos átomos de carbono, y/o un grupo metileno puede estar substituido en posición 3 de un grupo cicloalquilenimino de 5 miembros con un átomo de azufre, un grupo sulfinilo o sulfonilo o un grupo metileno puede estar substituido en posición 4 de un grupo cicloalquilenimino de 6 a 7 miembros con un átomo de oxígeno o azufre, un grupo carbonilo, sulfinilo o sulfonilo o con un grupo NH eventualmente substituido con un grupo alquilo C1-3, hidroxi, formilo o alquilcarbonilo C1-3, en donde un grupo metileno adyacente al grupo NH indicado precedentemente eventualmente substituido puede estar substituido con un grupo carbonilo, sulfinilo o sulfonilo, con la condición de que en la substitución de los radicales cicloalquilenimino de 6 a 7 miembros indicados anteriormente, en los que un grupo metileno se substituyó con un átomo de oxígeno o azufre, con un grupo sulfinilo o sulfonilo, dos heteroátomos estén separados entre sí por al menos dos átomos de carbono, un grupo cicloalquileniminocarbonilo o cicloalquileniminosulfonilo de 5 a 7 miembros substituido eventualmente con uno o dos grupos alquilo C1-3, amino-alquilo C1-3, alquilamino C1-3-alquilo C1-3, di-(alquil C1-3)-amino-alquilo C1-3, un grupo cicloalquilenimino-alquilo C1-3 de 4 a 7 miembros, cicloalquilamino C1-6-alquilo C1-3, fenilo, fenilalquilo C1-3, heteroarilo, heteroarilalquilo C1-3, aminocarbonilo, alquilaminocarbonilo C1-3, di-(alquil C1-3)-aminocarbonilo o con grupos cicloalquileniminocarbonilo de 4 a 7 miembros, en donde el enlace doble no está ligado al nitrógeno y puede condensarse con un grupo heteroarilo de 5 a 6 miembros, un grupo aminocarbonilo o aminosulfonilo eventualmente substituido con uno o dos grupos alquilo C1-5, alquenilo C2-3, alquinilo C2-3, cicloalquilo C3-6 o grupos cicloalquilenimino de 5 a 7 miembros, en donde los substituyentes pueden ser iguales o diferentes y en cada caso uno de los grupos alquilo C1-5 puede estar substituido con uno o dos grupos hidroxi-alquilo C1-3, alcoxi C1-3-alquilo C1-3, benciloxi-alquilo C1-3, amino-alquilo C1-3, alquilamino C1-3-alquilo C1-3, di-(alquil C1-3)-amino-alquilo C1- 3, un grupo cicloalquilenimino C1-3-alquilo C1-3 de 4 a 7 miembros, un grupo alquiloxicarbonilamino C1-5-alquilo C1-3, cicloalquilamino C3-6-alquilo C1-3, aminocarbonilo, alquilamino C1-3-carbonilo, N-(cicloalquil C3-6)-alquilaminocarbonilo C1-3, N- (fenilalquil C1-3)-alquilaminocarbonilo C1-5, di-(alquil C1-3)-aminocarbonilo o un grupo cicloalquileniminocarbonilo de 4 a 7 miembros, un grupo alquilcarbonilo C1-7 o cicloalquilcarbonilo C3-7, en donde el grupo metileno puede estar substituido en la posición 2, 3 o 4 en un grupo cicloalquilcarbonilo C3-7 con un átomo de oxígeno o azufre, un grupo carbonilo, sulfinilo, sulfonilo o un grupo NH , en el cual el átomo de hidrógeno del grupo NH puede estar substituido con un grupo alquilo C1-3 o alquilcarbonilo C1-3, un grupo fenilcarbonilo o heteroarilcarbonilo, pueden estar substituidos en la parte fenilo o heteroarilo con un átomo de flúor, cloro o bromo, con un grupo trifluormetilo, alquilo C1-3, amino-alquilo C1-3, alquilamino C1-3- alquilo C1-3, di-(alquil C1-3)-amino-alquilo C1-3, cicloalquilenimino-alquilo C1-3 de 4 a 7 miembros o un grupo alcoxi C1-3, un grupo alquilo C1-3 monosubstituido eventualmente substituido con un grupo amino, alquilamino C1-3, di-(alquil C1-3)- amino, hidroxi, fenilo, heteroarilo o un grupo cicloalquilenimino de 4 a 7 miembros, en donde la parte fenilo puede estar substituida con un átomo de flúor, cloro o bromo, con un grupo trifluormetilo, alquilo C1-3, amino-alquilo C1-3, alquilamino C1- 3-alquilo C1-3, di-(alquil C1-3)-amino-alquilo C1-3, cicloalquilenimino-alquilo C1-3 de 4 a 7 miembros o un grupo alcoxi C1-3, y/o un grupo -CH2-CH2- de un grupo cicloalquilenimino de 5 a 7 miembros puede estar substituido con un grupo -NH-CO-, -CO- NH-, -CO-N(CH3)- o un grupo -N(CH3)-CO- o un grupo metileno adyacente al átomo de nitrógeno de un grupo cicloalquilenimino de 5 a 7 miembros puede estar substituido con un grupo carbonilo, o un grupo del grupo de fórmulas (2), en las cuales la parte heterocíclica en cada caso puede estar substituido un átomo de hidrógeno con un grupo alquilo C1-3, alquiloxicarbonilo C1-3, alquiloxicarbonilamino C1-5-alquilo C1-3, metilsulfonilmetilo, amino-alquilo C1-3, alquilamino C1-3-alquilo C1-3, di-(alquil C1-3)-amino-alquilo C1-3, un grupo cicloalquileniminoalquilo C1-3 de 4 a 7 miembros, morfolin-4-il-alquilo C1-3, piperazinil-alquilo C1-3, N-(alquil C1-3)-piperazin-4-il-alquilo C1-3, aminocarbonilo, alquilaminocarbonilo C1-3 o di-(alquil C1-3)- aminocarbonilo y m significa 1 o 2, R2 un átomo de hidrógeno, flúor, cloro o bromo, un grupo alquilo C1-3, en el cual los átomos de hidrógeno pueden estar substituidos total o parcialmente con un átomo de flúor, un grupo alquenilo C2-3, alquinilo C2- 3, alcoxi C1-3, un grupo mono, di o trifluorometoxi, R3 un átomo de hidrógeno o un grupo alquilo C1-3, R4 un átomo de hidrógeno o un grupo alquenilo C2-3 o alquinilo C2-3 o un grupo alquilo C1-5 lineal o ramificado, que eventualmente puede estar substituido con un átomo de flúor, un grupo mono, di o trifluorometilo, un grupo nitrilo, un grupo hidroxi, un grupo alquiloxi C1-3, en el cual los átomos de hidrógeno pueden estar total o parcialmente substituidos con un átomo de flúor, un grupo aliloxi, propargiloxi, benciloxi, alquilcarboniloxi C1-5, alquiloxicarboniloxi C1-5, carboxi-alquiloxi C1-3, alquiloxicarbonil C1-5-alquiloxi C1-3, alquiloxicarbonilamino C1-8, cloro-alquilaminocarbonilamino C1-3, mercapto, alquilsulfanilo C1-3, alquilsulfinilo C1-3, alquilsulfonilo C1-3, alquilcarbonilamino-alquilsulfanilo C1-3, alquilcarbonilamino-alquilsulfinilo C1-3, alquilcarbonilamino-alquilsulfonilo C1-3, carboxi, alquiloxicarbonilo C1-3, aliloxicarbonilo, propargiloxicarbonilo, benciloxicarbonilo, aminocarbonilo, alquilaminocarbonilo, di-(alquil)-aminocarbonilo, aminosulfonilo, amino, alquilamino C1-3, di-(alquil C1-3)-amino, alquilcarbonilamino C1-5, alquilsulfonilamino C1-3, N-(alquilsulfonilo C1-3)-alquilamino C1-3, cicloalquilcarbonilamino C3-6, aminocarbonilamino, alquilaminocarbonilamino C1-3, di-(alquil C1-3)-carbonilamino, un grupo cicloalquileniminocarbonilamino de 4 a 7 miembros, benciloxicarbonilamino, fenilcarbonilamino heteroarilo o un grupo guanidino, un grupo de la fórmula general -(CH2)o-N(R11)-C(O)-A, en la cual o es uno de los números 2, 3, 4 ó 5, R11 es un átomo de hidrógeno o un grupo alquilo C1-3 y A es un grupo heteroarilo o un grupo cicloalquilo C5-7, en el cual el grupo metino puede estar substituido en posición 1 con un átomo de nitrógeno y/o un grupo metileno puede estar substituido con un átomo de oxígeno o azufre, un grupo -NH-, -N(OH)-, -N(alquil C1-3)-, -N(alquilcarbonil C1-3)-, o -N(heteroarilo)- y/o un grupo metileno adyacente a un grupo -NH-, -N(OH)-, -N(alquil C1-3)-, -N(alquilcarbonil C1-3)-, o -N(heteroarilo)- puede estar adicionalmente substituido con un grupo carbonilo, sulfinilo o sulfonilo, un grupo cicloalquileniminocarbonilalquilo C1-3 de 4 a 7 miembros, en donde un grupo metileno de la parte cicloalquilenimino puede estar substituido con un grupo alquilo C1-3 eventualmente substituido con un
ARP030104741A 2002-12-19 2003-12-19 Amidas sustituidas de acido carboxilico, su preparacion y su uso como medicamentos Suspension/Interruption AR044495A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2002159407 DE10259407A1 (de) 2002-12-19 2002-12-19 Neue Carbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
DE10335545A DE10335545A1 (de) 2003-08-02 2003-08-02 Neue Carbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
AR044495A1 true AR044495A1 (es) 2005-09-14

Family

ID=32683452

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104741A Suspension/Interruption AR044495A1 (es) 2002-12-19 2003-12-19 Amidas sustituidas de acido carboxilico, su preparacion y su uso como medicamentos

Country Status (11)

Country Link
US (2) US7326791B2 (es)
EP (1) EP1575925A1 (es)
JP (1) JP2006514987A (es)
AR (1) AR044495A1 (es)
AU (1) AU2003292239A1 (es)
CA (1) CA2510846A1 (es)
CL (1) CL2003002665A1 (es)
PE (1) PE20040804A1 (es)
TW (1) TW200504032A (es)
UY (1) UY28128A1 (es)
WO (1) WO2004056784A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10260730A1 (de) * 2002-12-23 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte stickstoffhaltige Heterobicyclen, deren Herstellung und deren Verwendung als Arzneimittel
US7371743B2 (en) 2004-02-28 2008-05-13 Boehringer Ingelheim International Gmbh Carboxylic acid amides, the preparation thereof and their use as medicaments
US7504413B2 (en) 2004-05-06 2009-03-17 Cytokinetics, Inc. N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases
US7795448B2 (en) 2004-05-06 2010-09-14 Cytokinetics, Incorporated Imidazoyl-benzamide anti-cancer agents
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
DE102004027821A1 (de) * 2004-06-08 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Benzimidazole, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
CN101083985A (zh) 2004-09-21 2007-12-05 幸讬制药公司 用于炎症及免疫相关用途的化合物
UA92907C2 (uk) * 2005-02-25 2010-12-27 Серенекс, Інк. Похідні тетрагідроіндазолону
CN101268048A (zh) * 2005-09-16 2008-09-17 瑟瑞耐克斯有限公司 咔唑衍生物
JP2009532329A (ja) * 2006-02-27 2009-09-10 セレネックス， インコーポレイテッド シクロヘキシルアミノ、ベンゼン、ピリジン及びピリダジン誘導体
TW200902533A (en) * 2007-05-02 2009-01-16 Boehringer Ingelheim Int Carboxylic acid amides, manufacturing and use thereof as medicaments
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
JP5524852B2 (ja) 2007-11-15 2014-06-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換アミド、それらの製造及び医薬品としての使用
US8278313B2 (en) 2008-03-11 2012-10-02 Abbott Laboratories Macrocyclic spiro pyrimidine derivatives
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
JP5973994B2 (ja) 2010-09-13 2016-08-23 大塚製薬株式会社 複素環化合物
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
JP6166996B2 (ja) * 2013-09-27 2017-07-19 株式会社日本ファインケム ヒドラジノアリールカルボン酸類の製造方法
CA2933632C (en) 2013-12-24 2022-06-21 Oncotartis, Inc. Benzamide and nicotinamide compounds and methods of using same
EP3134406A1 (en) * 2014-04-24 2017-03-01 Dart Neuroscience (Cayman) Ltd Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2h-pyrazolo [4,3-c]pyridine compounds as glyt1 inhibitors
TWI601712B (zh) 2014-11-05 2017-10-11 達特神經科學（開曼）有限責任公司 作為ｇｌｙｔ１抑制劑之經取代之氮雜環丁基化合物
CN109475530B (zh) * 2016-05-23 2022-03-01 洛克菲勒大学 用于治疗自身免疫性疾病的氨酰基吲唑免疫调节剂
MA51610A (fr) * 2018-01-15 2021-04-21 UCB Biopharma SRL Dérivés d'imidazole fusionnés utilisés en tant qu'inhibiteurs d'il-17
EP4095129A4 (en) * 2020-01-17 2023-10-25 Boris Slavinovich Farber BENZIMIDAZOLE DERIVATIVES AND SALTS THEREOF WITH ANTIGERIATRICAL EFFECT
CN114262322A (zh) * 2020-09-16 2022-04-01 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
AU2022276958A1 (en) * 2021-05-17 2023-12-07 Hk Inno.N Corporation Benzamide derivative, method for preparing same, and pharmaceutical composition for prevention or treatment of cancer containing same as active ingredient
CN113773260B (zh) * 2021-08-26 2023-09-22 华南师范大学 一种类共价有机材料及其制备方法和应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
DE4007535A1 (de) * 1990-03-09 1991-09-12 Hoechst Ag Wasserunloesliche azofarbmittel, ihre herstellung und verwendung
WO1996000730A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
CA2272285C (en) * 1997-01-23 2006-11-21 Yamanouchi Pharmaceutical Co., Ltd. Amide derivatives and medicinal compositions thereof
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
US6414008B1 (en) 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
US6114532A (en) 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
WO1999040072A1 (de) * 1998-02-03 1999-08-12 Boehringer Ingelheim Pharma Kg 5-gliedrige benzokondensierte heterocyclen als antithrombotika
TWI248435B (en) * 1998-07-04 2006-02-01 Boehringer Ingelheim Pharma Benzimidazoles, the preparation thereof and their use as pharmaceutical compositions
US6248770B1 (en) 1998-07-09 2001-06-19 Boehringer Ingelheim Pharma Kg Benzimidazoles having antithrombotic activity
CA2340100A1 (en) 1998-08-11 2000-02-24 Daiichi Pharmaceutical Co., Ltd. Novel sulfonyl derivatives
AU1707700A (en) 1998-10-29 2000-05-22 Bristol-Myers Squibb Company Novel inhibitors of impdh enzyme
BR0009539A (pt) * 1999-04-02 2006-06-06 Neurogen Corp composto, composição farmacêutica, método para tratamento ou prevenção de uma doença ou distúrbio associado com agonismo patogênico, agonismo inverso ou antagonismo do receptor gaba a, uso de um composto, método para localizar receptores gaba a em uma amostra de tecido, método para alterar a atividade transdutora de sinal de receptores gaba a, método para o tratamento ou prevenção de distúrbios psicológicos associados com modulação do complexo receptor gaba a, e, processo para a preparação de um composto
CA2382751A1 (en) 1999-05-24 2000-11-30 Cor Therapeutics, Inc. Inhibitors of factor xa
JP2003502314A (ja) 1999-06-14 2003-01-21 イーライ・リリー・アンド・カンパニー 化合物
EP1192135A2 (en) 1999-06-14 2002-04-03 Eli Lilly And Company Serine protease inhibitors
DE19962329A1 (de) * 1999-12-23 2001-06-28 Boehringer Ingelheim Pharma Benzimidazole, deren Herstellung und deren Verwendung als Arzneimittel
US6451832B2 (en) 1999-12-23 2002-09-17 Boehringer Ingelheim Pharma Kg Benzimidazoles with antithrombotic activity
TWI288745B (en) 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
GB0030304D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030305D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030306D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
WO2002026720A2 (en) 2000-09-29 2002-04-04 Millennium Pharmaceuticals, Inc. PIPERAZINE BASED INHIBITORS OF FACTOR Xa
DE10111842A1 (de) 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Antithrombotische Carbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
US20020183519A1 (en) 2001-03-13 2002-12-05 Herbert Nar Antithrombotic carboxylic acid amides
US7429597B2 (en) 2002-12-23 2008-09-30 Boehringer Ingelheim Pharma Gmbh & Co., Kg Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions
US7371743B2 (en) 2004-02-28 2008-05-13 Boehringer Ingelheim International Gmbh Carboxylic acid amides, the preparation thereof and their use as medicaments
DE102004027821A1 (de) * 2004-06-08 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Benzimidazole, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
UY28128A1 (es) 2004-07-30
JP2006514987A (ja) 2006-05-18
TW200504032A (en) 2005-02-01
AU2003292239A1 (en) 2004-07-14
AU2003292239A8 (en) 2004-07-14
CL2003002665A1 (es) 2005-01-14
CA2510846A1 (en) 2004-07-08
US20080132496A1 (en) 2008-06-05
US7326791B2 (en) 2008-02-05
EP1575925A1 (de) 2005-09-21
PE20040804A1 (es) 2004-12-31
US20040220169A1 (en) 2004-11-04
WO2004056784A1 (de) 2004-07-08

Similar Documents

Publication Publication Date Title
AR044495A1 (es) Amidas sustituidas de acido carboxilico, su preparacion y su uso como medicamentos
AR052177A1 (es) Medicamentos para el tratamiento o la prevencion de enfermedades fibroticas
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR048959A1 (es) Amidas sustituidas del acido tiofencarboxilico; su obtencion y su uso como medicamentos con efecto antitrombotico.
AR053092A1 (es) Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis
CY1112916T1 (el) 3-ζ-1-(4-(ν-((4-μεθυλ-πιπεραζιν-1-υλ)-μεθυλκαρβονυλ)-ν-μεθυλ-αμινο)-ανιλινο)-1-φαινυλ-μεθυλενο-6-μεθοξυκαρβονυλ-2-ινδολινονη-μονοαιθανοσουλφονικη και η χρηση αυτης ως φαρμακευτικη συνθεση
AR049588A1 (es) Saliciltiazoles sustituidos con difenilamina o derivados de difenilamina como inhibidores de receptores ptp1b
DK1794126T3 (da) Krystallinsk form af N-(-4-fluorbenzyl)-N-(1-methylpiperidn-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamid-hemitartrat
AR035205A1 (es) Compuestos utiles en el tratamiento de enfermedades inflamatorias, proceso para su preparacion, intermediarios y composiciones farmaceuticas
AR057815A1 (es) Acidos propanoicos sustituidos por 3-(4-hidroxi-fenilo) con restricciones conformacionales que resultan de utilidad para el tratamiento de trastornos metabolicos
HRP20130075T1 (hr) S-TRIAZOLIL ALFA-MERKAPTOACETANILIDI KAO INHIBITORI REVERZNE TRANSKRIPTAZE HIV-a
AR086538A1 (es) COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE
AR047823A1 (es) Derivados de 1,2,3,4-tetrahidroisoquinolina sustituida
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CO5611135A2 (es) Nuevos derivados de piperidina como moduladores de la actividad de quimioquina, procesos para su preparacion y composiciones farmaceuticas que los contienen
AR073480A1 (es) Benzamidas, su preparacion y su uso como medicamentos
ES2258642T3 (es) Derivados de piperidina utiles como moduladores de la actividad del receptor de quimiocina.
CY1108445T1 (el) Νεα μεθοδος συνθεσης και νεα κρυσταλλικη μορφη της αγομελατινης καθως και φαρμακευτικες συνθεσεις που την περιεχουν
AR069596A1 (es) Regulador del crecimiento de plantas
AR060990A1 (es) Acidos carboxilicos sustituidos con fenilaminobenzoxazol y composiciones farmaceuticas que los contienen, utilizadas para el tratamiento de la diabetes
AR084768A1 (es) Moduladores de la senda de complemento y usos de los mismos
AR036347A1 (es) Compuestos heterociclicos con actividades hipolipidemicas e hipocolesterolemicas, el proceso para su preparacion,las composiciones farmaceuticas que los contienen y su uso en medicina.
ATE368655T1 (de) Stickstoffhaltige heterocyclische verbindung und arzneimittel davon
AR037754A1 (es) Herbicidas

Legal Events

Date Code Title Description
FB Suspension of granting procedure